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Abstract  
Background 
Thirty-day mortality after treatment for lung cancer is a measure of unsuccessful outcome and 
where treatment should have been avoided. Guidelines recommend offering chemotherapy to 
individuals with small cell lung cancer (SCLC) who have poorer performance status (PS) 
because of its high initial response rate. However, this comes with an increased risk of toxicity 
and early death. We quantified real-world 30-day mortality in SCLC following chemotherapy, 
established the factors associated with this and compared these to the factors that influence 
receipt of chemotherapy. 
Methods 
We used linked national English datasets to define the factors associated with both receiving 
chemotherapy and 30-day mortality following chemotherapy.  
Results 
We identified 3,715 people diagnosed with SCLC, of which 2,235 (60.2%) received 
chemotherapy. There were 174 (7.8%) deaths within 30 days of chemotherapy. The adjusted 
odds of receiving chemotherapy decreased with older age, worsening PS and increasing 
comorbidities. Thirty-day mortality was independently associated with poor PS (PS 2 vs PS 0 
adjusted OR 3.75 95% CI 1.71-8.25) and stage (extensive vs limited adjusted OR 1.68 95% 
CI 1.03-2.74) but in contrast was not associated with increasing age. Both chemotherapy 
administration and 30-day mortality varied by hospital network. 
Conclusions 
To reduce variation in chemotherapy administration predictors of 30-day mortality could be 
used as an adjunct to improve sub-optimal patient selection. We have quantified 30-day 
mortality risk by the two independently associated factors, PS and stage, so that patients and 
clinicians can make better informed decisions about the potential risk of early death following 
chemotherapy.  
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CAV- Cyclophosphamide, doxorubicin and vincristine 
CbE- Carboplatin + etoposide SCLC- Small cell lung cancer 
CI – Confidence interval 
ED-SCLC- Extensive stage small cell lung cancer 
EP- Cisplatin + etoposide 
LD-SCLC- Limited stage small cell lung cancer 
NLCA- National lung cancer audit 
OR- Odds ratio 
PS- Performance status 
SACT- Systemic anti-cancer therapies 
TNM- Tumour, Node Metastasis  
WHO- World health organisation 
VALSG- Veterans Administration Lung Study Group 
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Introduction  
The median survival for people with small cell lung cancer (SCLC) who do not receive 
chemotherapy is short, and this, coupled with the fact that this aggressive tumour is 
responsive to chemotherapy reflects treatment guidelines which recommend 
chemotherapy for extensive stage (ED-SCLC) even in elderly people with poor 
performance status (PS) and significant comorbidities.1-4 Administration of 
chemotherapy in this frail population means some individuals die shortly after 
treatment. It is recognised that deaths within 30 days of anti-cancer treatment are an 
indicator of avoidable harm and sub-optimal patient selection as they reflect that 
treatment was either; directly toxic or, in the case of non-treatment related early death 
e.g. disease progression, was futile and unnecessary.5 To minimise 30-day mortality 
and improve patient selection for chemotherapy we have determined what factors 
influence receipt of chemotherapy and investigated how these are associated with 30-
day mortality from the first chemotherapy dose. 
Materials and Methods 
Study population 
Ethical approval for this study was obtained from the NHS Health Research Authority 
(16/LO/0503). Our primary dataset, the National Lung Cancer Audit (NLCA), consisted 
of people diagnosed with lung cancer in English hospitals between 1st January 2015 
and 31st December 2015. These data were linked with Systemic Anticancer Therapies 
(SACT) and Hospital Episode Statistics data. All data were prospectively collected via 
clinical coding or electronic prescription. People with SCLC were identified from their 
systematized nomenclature of medicine histological code.  
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Chemotherapy 
If an individual had a date for administration of chemotherapy recorded within 6 
months from the date of diagnosis, they were defined as having received 
chemotherapy. Those who did not have a date for chemotherapy administration or 
received chemotherapy after 6 months from diagnosis were assumed not to have 
received chemotherapy. We defined the location where chemotherapy was received 
by lung cancer network. In England, there are 13 cancer networks based on 
geographical location and each is composed of several hospitals. The chemotherapy 
received was grouped according to the combination administered. The remaining 
groups were: Single platinum (cisplatin or carboplatin), other (single agent etoposide, 
topotecan and clinical trials) and missing (date of administration present but no drug 
details given).  
Death date 
We used a death date derived from the Office of National Statistics records. For this 
study, the date of death had last been updated on the 19th October 2016. We used 
these dates along with the SACT record for date of first chemotherapy dose received 
to calculate 30-day mortality.  
Covariates 
Our variables were primarily derived from NLCA data. Socioeconomic status was 
calculated from postcode of residence and formatted into Townsend index of 
deprivation (1- least to 5 –most).  PS is a marker of a person’s well-being and fitness. 
It is based upon WHO criteria (0- asymptomatic to 4- bedbound, unable to carry out 
self-care) and taken at the time of diagnosis.  
Stage was obtained from pre-treatment tumour node metastases (TNM) records. We 
divided stage into limited (LD-SCLC) and extensive (ED-SCLC), based on similar 
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criteria to the Veterans Administration Lung Study Group (VALSG).6 ED-SCLC 
consisted of any tumour with M1a/b or any T and M0 with N3 nodal involvement. If 
TNM was not recorded stage was classed as missing.   
We used a previously derived method to calculate a Charlson comorbidity index using 
a list of diagnoses (excluding lung cancer) from previous hospital admissions up to the 
date of chemotherapy.7,8 People with no hospital admissions or comorbidities were 
assigned a score of 0. The Charlson index was grouped into 4 categories (0, 1, 2-3 
and ≥4). 
Statistical analysis 
All analyses were completed using Stata V15 (Stata Corp, TX, USA). We performed 
a descriptive analysis of the whole cohort and those who received chemotherapy. We 
then did multiple logistic regression to estimate odds ratios for receiving chemotherapy 
and adjusted for the aforementioned factors along with cancer network where 
chemotherapy was given or where the patient was first seen (if chemotherapy was not 
given).  
We calculated the proportion of deaths within 30 days for those who received 
chemotherapy. We used multiple logistic regression to estimate odds ratios (OR) for 
30-day mortality by patient, tumour, chemotherapy and network factors in those who 
received chemotherapy. Our final logistic regression model contained factors that were 
a-priori (age, sex, social deprivation) or showed significant association with early death 
on univariate analysis (p<0.05). We assessed the significance of each variable by 
using the likelihood ratio test or Wald’s p value.  
We compared lung cancer network performance with receipt of chemotherapy and 30-
day mortality by generating a pooled mean national proportion for both outcome 
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measures. Then, in a separate multiple logistic regression model, adjusting for our 
measured factors, we clustered patients by network and generated odds ratios of 
receiving chemotherapy and early death for each network by comparing with the mean 
national proportion. 
Results 
We identified 3,715 individuals with SCLC. The cohort demographics are shown in 
Table 1. The median age was 70 years (IQR 63-76). Most people had ED-SCLC 
(n=2,818 (75.8%)) whilst 785 (21.1%) had LD-SCLC. Stage and PS were not recorded 
in 112 (3.0%) and 1,031 (27.8%) people respectively.  
A total of 2,235 people (60.2%) received chemotherapy, 1,133 (50.7%) were male. 
The median age of those who received chemotherapy was 69 years (IQR 62-74) and 
1,130 (50.5%) had a PS of 0-1, 421 people (18.8%) had a PS of 2 and 160 (7.2%) had 
a PS of 3-4. PS was not recorded for 524 (23.5%) people. The chemotherapy 
administered by lung cancer stage is shown in Table 2. 
Receiving chemotherapy 
There was a reduction in the odds of receiving chemotherapy with increasing age 
(Table 1). The adjusted OR for those aged 50-59 years vs. those aged 70-79 years 
was 1.61 (95% CI 1.25-2.06). Worsening PS was associated with less chance of 
receiving chemotherapy (PS 3 vs PS 0, adjusted OR 0.28 95% CI 0.21-0.38). People 
with a Charlson comorbidity index of ≥4, were less likely to receive chemotherapy 
compared to those with no comorbidity (adjusted OR 0.52 95% CI 0.42-0.64). Sex, 
social deprivation and stage did not affect receipt of chemotherapy. When compared 
to the national proportion of people treated there was significant variation in the odds 
of receiving chemotherapy by cancer network, this is demonstrated in Figure 1. Three 
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networks were less likely to administer chemotherapy and 3 were more likely. The 
odds ranged from 0.70 (95% CI 0.56-0.88) to 1.95 (95% CI 1.36-2.80).  
30-day mortality 
The median survival from diagnosis to death for individuals who received 
chemotherapy was 406 days (95% CI 386-420) and 244 days (95% CI 233-253) for 
LD-SCLC and ED-SCLC respectively. This was markedly different for people who did 
not receive chemotherapy (LD-SCLC 300 days (95%CI 262-308 days) and ED-SCLC 
36 days (95% CI 32-39 days)). 
The overall 30-day mortality after chemotherapy was 7.8% (n=174). This was 
associated with patient, tumour and geographical factors (Table 3). Worsening PS, 
was overwhelmingly associated with 30-day mortality. The adjusted odds ratio for 
people with PS 2 vs PS 0 was 3.75 (95% CI 1.71-8.25). People ≥80 years were less 
likely to die within 30 days compared to people aged 70-79 years (adjusted OR 0.42 
95% CI 0.20-0.91) however, there was no trend across all ages (p trend= 0.8). ED-
SCLC was associated with greater odds of early death (adjusted OR 1.68 95% CI 
1.03-2.74). Early mortality was not independently associated with the chemotherapy 
received, however, there was a signal that a single platinum agent increased 30-day 
mortality risk compared to carboplatin + etoposide (CbE) (adjusted OR 1.71 95% CI 
0.99-2.95). There was significant variability in 30-day mortality by cancer network (p 
<0.001). Figure 2 shows the case-mix adjusted proportion of patients who died within 
30 days of chemotherapy by different network and demonstrates that one network had 
an increased proportion of deaths while another had significantly fewer. There was no 
correlation between the proportion of individuals treated and the proportion of early 
deaths by network (p=0.487). 
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Discussion 
Main findings 
From these observational data we have found that the administration of chemotherapy 
for SCLC was associated with PS, age, comorbidity and cancer network. The preferred 
choice of chemotherapy in LD-SCLC was CbE followed by cisplatin + etoposide (EP). 
In ED-SCLC CbE was preferred followed by single platinum.  
We have quantified the up to date median survival for people who do not receive 
chemotherapy in SCLC and have shown that the difference between ED-SCLC and 
LD-SCLC is much greater than previously thought.1 Thirty-day mortality was 
associated with stage and PS and varied by network. Although increasing age did not 
show a trend, people aged ≥80 years were less likely to die within 30 days, yet, were 
also less likely to receive chemotherapy.  
Strengths 
This is the first time that factors associated with 30-day mortality have been explored 
in detail for SCLC using real-world data. Clinical trials provide limited data on 30-day 
mortality and compared to these, our study population is unselected and therefore 
more relevant to clinical practice. We have demonstrated variation in SCLC treatment 
and outcomes in England but this finding will be relevant to other countries. The 
untreated median survival in SCLC is often cited from VALSG research conducted in 
the 1970s but we have described the current median survival, this is important as 
healthcare has changed with time.1 
Limitations 
Our dataset consisted of histologically confirmed SCLC but there is a small proportion 
of patients who were diagnosed with lung cancer that were too frail to obtain a 
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histological diagnosis. This number is too small to affect our findings as histological 
confirmation for lung cancers diagnosed in 2015 was reported as 74% in the NLCA.9 
Radiotherapy data was limited. Radiotherapy may add further toxicity to 
chemotherapy, however, it is not usually given in the first 30 days. We cannot describe 
the causes of early death, though, the information that matters to the patient is the risk 
of death from any cause. We have reported stage based on VALSG criteria. TNM 
staging offers a more precise method of grouping patients, however, using this would 
result in subgroups being too small for our statistical analysis. Similarly, guidelines use 
VALSG criteria to recommend treatment, hence, our findings can be easily related to 
these. 
 
Comparisons with other research 
Receipt of chemotherapy 
The findings of increasing age, poorer PS, greater comorbidity and network have all 
been associated with a negative effect on the likelihood of receiving chemotherapy.10-
12 PS is a subjective measure by the clinician and therefore one expects this to 
correlate with receiving chemotherapy as the clinician also controls the prescription.  
Rich et al identified that patients were more likely to receive chemotherapy if they were 
diagnosed in a hospital recruiting for clinical trials.10 This may explain the differences 
between networks in our study as some contain more clinical trial units than others. 
However, ambiguous selection criteria and expertise may also contribute to variation. 
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Chemotherapy 
Some of the chemotherapy given, such as CAV, is not recommended in current 
guidelines. Previously CAV was favoured in poor prognosis SCLC, unlike EP, which 
was not used for this group.13 A survey conducted  20 years ago found CbE was 
favoured over EP because of patient convenience, toxicity and quality of life.13 This 
may explain why CbE was favoured for LD-SCLC in our study. 
30-day mortality 
Our finding that 30-day mortality was 4.0% and 9.1% for people with LD-SCLC and 
ED-SCLC respectively, is similar to Wallington et al’s study (4.0% for curative intent  
chemotherapy  and 12.0% for palliative intent).14 Likewise, a systematic review of 
phase III clinical trials in SCLC found that 2.95% of people died within 4 weeks of 
completing chemotherapy.15 In this study the population mostly consisted of 
individuals with PS 0-1 and deaths that were a result of disease progression were 
excluded. With these caveats considered our findings are similar when 30-day 
mortality risk is stratified by PS and stage, as shown in Table 4.  
We found the oldest age group had a lower risk of death with no significant trend 
across all ages. Despite this, the oldest group were less likely to receive 
chemotherapy. This contrasts with previous research which assessed overall survival 
in patients entered into clinical trials for chemotherapy in SCLC.16 They found that 
increasing age was a risk factor for death. The most likely explanation is that the oldest 
patients in our study who received chemotherapy were in fact fitter than their younger 
counterparts. This originates from them either being less likely to be offered or accept 
chemotherapy when fitness levels are equivalent to younger patients.  
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Comorbidity was not independently associated with early mortality. In previous work, 
we found that an increase in Charlson index was associated with reduced overall 
survival.10 Our discrepancies are explained by the different length survival was 
measured. Thirty days is a short time-frame and if survival is measured over longer 
periods it permits an increased exposure time to the slower rate of death from 
comorbidities to occur.8 Similarly, chemotherapy given to people with more 
comorbidities might be under-dosed.  
Using more than 2 chemotherapy drugs in combination is linked with increased early 
treatment-related deaths in SCLC.17,18 Contrary to this we found a signal that a single 
platinum agent increased 30-day mortality risk when compared to CbE. Selection bias 
may explain this i.e. frailer individuals were given a single chemotherapy drug to limit 
toxicity. If this is the case then it implies that an “all or nothing” approach should be 
taken for combination chemotherapy. 
Median survival 
In our study, the median survival for untreated LD-SCLC was considerably longer than 
Zelen et al’s estimate of 11.7 weeks.1 This difference is explained by the broad range 
of TNM stages captured under the limited stage umbrella, differing cohort sizes (Zelen 
et al n=38) and the advances of routine healthcare since the 1970s.  
Relevance 
Our research demonstrates geographical variation in the administration of 
chemotherapy for SCLC with no apparent correlation to the risk of 30-day mortality, 
indicating uncertainty in patient selection. In surgery for lung cancer global risk scores 
have been proposed as an aid to inform shared decision making, but none are yet 
considered accurate enough for this purpose.19-21 Instead, tables have been produced 
showing recent mortality figures stratified by the most important associated factors.19 
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We propose that a similar method should be considered when assessing eligibility for 
chemotherapy and have therefore stratified 30-day mortality risk by the two 
independently associated factors PS and stage (Table 4). However, further work is 
needed to develop a robust risk prediction model for 30-day mortality following 
chemotherapy which could incorporate other biological markers.22-24 
Conclusion 
The degree of physical impairment, as reflected in PS, is the overwhelming factor 
determining receipt of chemotherapy and 30-day mortality. However, it is evident that 
age and comorbidity are given too much weight in the decision to administer 
chemotherapy which may result in suboptimal decision making and variation between 
networks. We propose that 30-day mortality risk can be used in conjunction with our 
median survival estimates to assist the patient selection process. Table 4 provides a 
practical solution to this, conveying 30-day mortality risk by the independently 
associated factors, PS and stage allowing better informed treatment decisions going 
forward. 
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Table 1: Features of patients who had chemotherapy and the odds ratios for receiving chemotherapy  
 Total population Had chemotherapy  
 
OR 
 
 
95% CI 
 
Adjusted 
OR* 
 
 
95% CI 
 
P value 
(LR test) 
 
Factor 
 
N= 3,715 
 
% 
 
N=2,235 (60.2%) 
 
% 
Sex 
Female 
Male 
1,797 
1,918 
48.4 
51.6 
1,102 
1,133 
61.3 
59.1 
1 
0.91 
 
0.80-1.04 
1 
0.97 
 
0.84-1.12 
 
0.666* 
Age group  
<50 
50-59 
60-69 
70-79 
≥80 
104 
477 
1,211 
1,401 
522 
2.8 
12.8 
32.6 
37.7 
14.1 
69 
342 
789 
852 
183 
66.3 
71.7 
65.2 
60.8 
35.1 
1.27 
1.63 
1.20 
1 
0.35 
0.83-1.93 
1.30-2.05 
1.03-1.41 
 
0.28-0.43 
1.20 
1.61 
1.16 
1 
0.37 
0.77-1.89 
1.25-2.06 
0.97-1.38 
 
0.29-0.46 
 
 
 
 
<0.001¥ 
Townsend Quintile 
Least deprived-1 
2 
3 
4 
Most deprived- 5 
466 
659 
698 
841 
1,051 
12.5 
17.8 
18.8 
22.6 
28.3 
278 
400 
424 
509 
624 
59.7 
60.7 
60.7 
60.5 
59.4 
1 
1.04 
1.05 
1.04 
0.99 
 
0.82-1.33 
0.82-1.33 
0.82-1.31 
0.79-1.23 
1 
1.01 
1.11 
1.02 
0.92 
 
0.77-1.32 
0.85-1.45 
0.79-1.32 
0.71-1.18 
 
 
 
 
0.568 
Performance status 
0 
1 
2 
3 
4 
Missing 
450 
1,031 
663 
423 
117 
1,031 
12.1 
27.8 
17.9 
11.4 
3.2 
27.8 
334 
796 
421 
148 
12 
524 
74.2 
77.2 
63.5 
35.0 
10.3 
50.8 
1 
1.18 
0.60 
0.19 
0.04 
0.36 
 
0.91-1.52 
0.46-0.79 
0.14-0.25 
0.02-0.07 
0.28-0.46 
1 
1.44 
0.85 
0.28 
0.05 
0.44 
 
1.11-1.97 
0.64-1.13 
0.21-0.38 
0.03-0.10 
0.34-0.58 
 
 
 
 
 
<0.001  
Charlson comorbidity index 
0 
1 
2-3 
≥4 
625 
575 
514 
2,001 
16.8 
15.5 
13.8 
53.9 
445 
426 
330 
1,034 
71.2 
74.1 
64.2 
51.7 
1 
1.16 
0.73 
0.43 
 
0.90-1.549 
0.56-0.93 
0.36-0.53 
1 
1.19 
0.86 
0.52 
 
0.91-1.57 
0.65-1.14 
0.42-0.64 
 
 
 
<0.001  
Stage 
Limited 
Extensive 
Missing 
785 
2,818 
112 
21.1 
75.9 
3.0 
547 
1,633 
55 
69.7 
57.9 
49.1 
1 
0.60 
0.42 
 
0.51-0.71 
0.28-0.63 
1 
0.88 
0.68 
 
0.73-1.08 
0.44-1.06 
 
 
0.191 
  
Network (separate logistic regression model to other factors) 
National pooled 
N1 
N2 
N3 
N4 
N5 
N6 
N7 
N8 
N9 
N10 
N11 
N12 
N13 
3,715 
214 
207 
441 
341 
490 
382 
287 
358 
294 
273 
103 
162 
163 
 
5.8 
5.6 
11.9 
9.2 
13.2 
10.3 
7.7 
9.7 
7.9 
7.4 
2.8 
4.4 
4.4 
2,235 
108 
120 
276 
178 
318 
237 
182 
196 
191 
137 
67 
119 
106 
60.2 
50.5 
58.0 
62.6 
52.2 
64.9 
62.0 
63.4 
54.7 
65.0 
50.2 
65.0 
73.5 
65.0 
1 
0.67 
0.91 
1.11 
0.72 
1.22 
1.08 
1.15 
0.80 
1.23 
0.67 
1.23 
1.83 
1.23 
 
0.52-0.87 
0.70-1.19 
0.92-1.33 
0.59-0.89 
1.03-1.46 
0.89-1.32 
0.91-1.43 
0.66-0.98 
0.98-1.55 
0.53-0.84 
0.83-1.84 
1.30-2.58 
0.90-1.69 
1 
0.88 
0.75 
1.0 
0.70 
1.31 
0.93 
1.24 
0.71 
1.30 
0.70 
1.33 
1.95 
1.45 
 
0.66-1.18 
0.57-1.00 
0.82-1.22 
0.56-0.88 
1.08-1.58 
0.75-1.15 
0.97-1.59 
0.57-0.89 
1.00-1.69 
0.54-0.90 
0.87-2.03 
1.36-2.80 
1.03-2.04 
 
 
 
 
 
 
 
 
 
 
 
 
 
<0.001‡ 
LR= likelihood ratio test, Adjusted for all other variables ¥: LR test trend *: Wald’s P value. ‡:LR test in multivariate logistic model without clustering 
15 
 
Table 2: Chemotherapy regimens received by lung cancer stage 
Chemotherapy regimen Number of people % of those who received 
chemotherapy 
Limited stage 
Carboplatin + etoposide 368 67.3 
Cisplatin + etoposide 104 19.0 
CAV 2 0.4 
Single platinum  32 5.9 
Other chemotherapy 10 1.8 
Missing 31 5.7 
Extensive stage 
Carboplatin + etoposide 1 257 77.0 
Cisplatin + etoposide 105 6.4 
CAV 17 1.0 
Single platinum  118 7.2 
Other chemotherapy 44 2.7 
Missing 92 5.6 
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Table 3: Features of patients who died within 30 days of receiving chemotherapy and odds ratios for death within 30 days 
 
 
Factor 
Total 30 
day 
deaths 
N=174 
% who died 
from those 
who received 
chemotherapy 
 
 
OR 
 
 
95% CI 
 
Adjusted 
OR 
 
 
95% CI 
 
P value 
(LR test) 
Sex 
Female 
Male 
80 
94 
7.3 
8.3 
1 
1.16 
 
0.85-1.58 
1 
1.12 
 
0.81-1.55 
 
0.491* 
Age group 
<50 
50-59 
60-69 
70-79 
≥80 
5 
19 
69 
73 
8 
7.3 
5.6 
8.8 
8.6 
4.4 
0.83 
0.63 
1.02 
1 
0.49 
0.33-2.14 
0.37-1.06 
0.72-1.44 
 
0.23-1.03 
0.87 
0.71 
1.13 
1 
0.42 
0.33-2.32 
0.41-1.22 
0.79-1.63 
 
0.20-0.91 
 
 
 
 
0.773¥ 
Townsend quintile 
Least deprived- 1 
2 
3 
4 
Most deprived- 5 
14 
32 
38 
41 
49 
5.0 
8.0 
9.0 
8.1 
7.9 
1 
1.64 
1.86 
1.65 
1.61 
 
0.86-3.13 
0.99-3.49 
0.88-3.09 
0.87-2.96 
1 
1.44 
1.55 
1.53 
1.57 
 
0.74-2.80 
0.81-2.98 
0.80-2.91 
0.83-2.98 
 
 
 
 
0.667 
Performance status 
0 
1 
2 
3-4 
Missing 
8 
42 
43 
30 
51 
2.4 
5.3 
10.2 
18.8 
9.7 
1 
2.27 
4.64 
9.40 
4.39 
 
1.05-4.89 
2.15-10.00 
4.20-21.05 
2.06-9.38 
1 
2.15 
3.75 
6.92 
4.17 
 
0.99-4.69 
1.71-8.25 
3.02-15.86 
1.93-9.04 
 
 
 
 
<0.001 
Charlson comorbidity index 
0 
1 
2-3 
≥4 
25 
19 
20 
110 
5.6 
4.5 
6.1 
10.6 
1 
0.78 
1.08 
2.00 
 
0.43-1.45 
0.59-1.99 
1.28-3.13 
1 
0.72 
0.94 
1.28 
 
0.38-1.36 
0.50-1.76 
0.80-2.06 
 
 
 
0.130 
Stage 
Limited 
Extensive 
Missing 
22 
149 
3 
4.0 
9.1 
5.5 
1 
2.40 
1.38 
 
1.51-3.79 
0.40-4.75 
1 
1.68 
1.12 
 
1.03-2.74 
0.31-4.04 
 
 
0.057 
Chemotherapy 
Carboplatin+ etoposide 
Cisplatin + etoposide 
CAV 
Other 
Single platinum 
Missing 
130 
7 
2 
5 
22 
8 
7.8 
3.2 
10.5 
9.1 
14.6 
6.3 
1 
0.39 
1.39 
1.18 
2.01 
0.79 
 
0.18-0.85 
0.32-6.08 
0.46-3.01 
1.24-3.27 
0.38-1.66 
1 
0.48 
1.59 
0.93 
1.71 
0.84 
 
0.21-1.07 
0.34-7.47 
0.35-2.49 
0.99-2.95 
0.38-1.82 
 
 
 
 
 
0.141 
  
Network (separate logistic regression model to other factors) 
Pooled networks 
N1 
N2 
N3 
N4 
N5 
N6 
N7 
N8 
N9 
N10 
N11 
N12 
N13 
174 
10 
6 
23 
6 
32 
20 
23 
10 
23 
7 
2 
4 
8 
7.8 
9.3 
5.0 
8.3 
3.4 
10.1 
8.4 
12.6 
5.1 
12.0 
5.1 
3.0 
3.4 
7.6 
1 
1.21 
0.62 
1.08 
0.41 
1.33 
1.09 
1.71 
0.64 
1.62 
0.64 
0.36 
0.41 
0.97 
 
0.64-2.28 
0.28-1.40 
0.72-1.60 
0.19-0.92 
0.95-1.85 
0.71-1.68 
1.14-2.58 
0.34-1.18 
1.08-2.44 
0.30-1.34 
0.09-1.48 
0.15-1.10 
0.48-1.96 
1 
1.10 
0.66 
1.10 
0.40 
1.17 
1.26 
1.79 
0.66 
1.50 
0.65 
0.39 
0.43 
1.03 
 
0.58-2.10 
0.29-1.51 
0.73-1.67 
0.18-0.88 
0.84-1.64 
0.81-1.96 
1.14-2.80 
0.36-1.23 
0.97-2.31 
0.31-1.35 
0.09-1.67 
0.16-1.15 
0.49-2.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.015‡ 
*: Wald’s P value test ¥: LR test for trend ‡: LR test in multivariate logistic model without clustering. Adjusted OR for all other factors 
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Table 4: Proportion of individuals who died within 30 days of receiving chemotherapy stratified by 
stage and performance status. 
  
 Table 4: Proportion of individuals who died within 30 days of 
receiving chemotherapy stratified by stage and performance 
status.  
 
 
 
Performance Status 
PS 0 PS 1 PS 2 PS 3-4 
St
ag
e 
 
 
Limited 
2.0% 
(0.0%-7.9%) 
(n=99) 
3.0%  
(1.4%-6.1%) 
(n=235) 
7.6%  
(3.3%-16.1%) 
(n=79) 
16.0% 
(5.7%-37.5%) 
(n=25) 
 
 
Extensive 
2.6% 
(1.1%-5.7%) 
(n=230) 
6.3% 
(4.6%-8.7%) 
(n=553) 
10.9%  
(7.8%-14.7%) 
(n=340) 
19.4% 
(13.5%-27.1%) 
(n=134) 
Parenthesis contains 95% confidence interval, n represents the total number of 
individuals who received chemotherapy in that group. 
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